Related Experiment Video
Updated: May 12, 2025
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Cabergoline's Promise in Endometriosis: Restoring Molecular Balance to Improve Reproductive Potential
Niloofar Shahgholi1, Zahra Noormohammadi2, Ashraf Moieni3,4,5
1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Objectives:
Endometriosis is a chronic gynecological condition characterized by abnormal angiogenesis and cell adhesion processes driven by VEGF-VEGFR-2 signaling. cabergoline, a dopamine agonist, has been shown to inhibit angiogenesis in endometriosis. This study investigates the therapeutic potential of cabergoline in modulating these pathways to mitigate endometriotic lesion progression and improve oocyte quality.
Design:
A randomized, placebo-controlled study was conducted, involving two groups of participants: one receiving cabergoline treatment and the other receiving a placebo.
Methods:
Eutopic endometrial tissue from women diagnosed with endometriosis was analyzed. VEGFR-2, FAK, PXN, ITGB3, and ITGAV expression levels were measured using qPCR. DNA methylation at the VEGFR-2 promoter was assessed using high-resolution melting analysis to examine epigenetic modifications. Western blot analysis was performed to evaluate the phosphorylation status of tyrosine residue 951 on the VEGFR-2 receptor, which is implicated in cell migration and survival. Oocyte quality was also assessed in both groups.
Results:
Cabergoline treatment reduced the expression levels of VEGFR-2, FAK, PXN, ITGB3, and ITGAV, with ITGAV showing a statistically significant decrease (p = 0.0174). Hypomethylation of the VEGFR-2 promoter was observed in the treatment group (p = 0.3566). However, phosphorylation of tyrosine residue 951 on VEGFR-2 significantly increased in the cabergoline-treated group (p = 0.004). Notably, oocyte quality significantly improved in the cabergoline group (p = 0.0318). A strong correlation was found between reduced VEGFR-2 expression (p = 0.0184), decreased promoter methylation (p = 0.0159), and downregulation of PTK2 expression (p = 0.0057), all of which are associated with improved oocyte quality.
Limitations:
The sample size was limited, and additional long-term studies are needed to confirm the therapeutic potential of cabergoline in endometriosis treatment.
Conclusions:
Cabergoline may enhance oocyte quality by modulating key regulators of the angiogenic pathway. These findings suggest its potential role in the management of endometriosis-related infertility, warranting further clinical investigation.
Insights
Cabergoline treatment for endometriosis reduced key angiogenic factors and improved oocyte quality. This suggests potential benefits for endometriosis-related infertility, though more research is needed.
Area of Science:
- Gynecology
- Reproductive Medicine
- Molecular Biology
Background:
- Endometriosis is a chronic gynecological condition marked by abnormal angiogenesis and cell adhesion.
- Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) signaling plays a critical role in endometriosis progression.
- Cabergoline, a dopamine agonist, has demonstrated anti-angiogenic properties relevant to endometriosis.
Purpose of the Study:
- To investigate the therapeutic potential of Cabergoline in modulating VEGF-VEGFR2 signaling pathways in endometriosis.
- To assess the impact of Cabergoline on endometriotic lesion progression and oocyte quality.
- To explore the effects of Cabergoline on gene expression and epigenetic modifications in endometrial tissue.
Main Methods:
- A randomized, placebo-controlled study involving Cabergoline treatment and placebo groups.
- Analysis of eutopic endometrial tissue for expression levels of VEGFR-2, FAK, PXN, ITGB3, and ITGAV using qPCR.
- Assessment of VEGFR-2 promoter DNA methylation via High-Resolution Melting (HRM) analysis and evaluation of VEGFR-2 phosphorylation status by Western blot.
- Oocyte quality assessment in both treatment and placebo groups.
Main Results:
- Cabergoline significantly reduced the expression of VEGFR-2, FAK, PXN, ITGB3, and ITGAV (p=0.0174 for ITGAV).
- Hypomethylation of the VEGFR-2 promoter was observed (p=0.3566), while phosphorylation of VEGFR-2 at tyrosine 951 significantly increased (p=0.004).
- Oocyte quality significantly improved in the Cabergoline group (p=0.0318), correlating with reduced VEGFR-2 expression and PTK2 downregulation.
Conclusions:
- Cabergoline may improve oocyte quality by modulating key regulators of the angiogenic pathway in endometriosis.
- The findings suggest a potential role for Cabergoline in managing endometriosis-related infertility.
- Further long-term clinical studies are warranted due to the limited sample size and to confirm therapeutic efficacy.
Related Concept Videos
02:07Oogenesis
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:27Ovarian Cycle